When to consider a Refractive Enhancement

Vance

Financial Disclosures

AdOM: Consultant/Equity Owner Alcon Laboratories: Consultant/Research **AI Optics: Equity Owner** Allotex: Consultant/Advisor/Equity Owner **Avisi Technologies, Inc: Consultant/Equity Owner Bausch & Lomb: Consultant/Advisor/Research Balance Ophthalmics: Consultant/Equity Owner/Research BVI: Consultant/Research Carl Zeiss Meditec: Consultant/Research** Centricity: Consultant/Advisor/Equity **Owner/Research Crystilex: Consultant/Equity Owner CSO: Consultant D&D** Biopharmaceuticals: Consultant/Equity Owner **DelSiTech: Consultant Euclid Vision Group: Consultant/Equity Owner Expert Opinion: Consultant/Equity Owner** eyeBrain Medical Inc: Consultant/Equity Owner **Eyedetec: Consultant/Equity Owner Eyesafe: Consultant/Equity Owner Fontana Biosciences: Equity Owner**

Forsight Robotics: Consultant/Equity Owner Glaukos: Consultant/Research/Equity Owner **Greenman: Consultant/Equity Owner** iVeena: Consultant/Equity Owner Johnson & Johnson: Consultant/Research LayerBio: Consultant/Equity Owner LensAr: Consultant/Equity Owner Lightfield Medical: Consultant/Equity Owner **Medevise: Consultant/Equity Owner** Melt Pharmaceuticals: Consultant/Equity Owner /Research Nanodrops: Consultant/Equity Owner **Nordic Pharma: Consultant Ocular Therapeutix: Research Oculotix: Consultant/Equity Owner ORA: Research Rayner: Consultant/Equity Owner/Research Reopia: Consultant/Equity Owner RxSight: Consultant/Research/Equity Owner Singular Strategies: Equity Owner Staar: Consultant/Research Stepwise Medical: Consultant/Equity Owner**




Stuart Therapeutics: Consultant/Equity Owner Sofia Biologics, Inc: Consultant/Equity Owner Surface Pharmaceuticals Inc: Consultant/Equity Owner

Tarsus Rx: Consultant/Equity Owner TearClear: Consultant/Equity Owner TearOptix: Consultant/Equity Owner TherOptix: Consultant/Equity Owner/Research Treehouse Eyes: Consultant/Equity Owner True North: Equity Owner Trukera: Consultant Vance Thompson Vision: Consultant/Equity Owner Visionary Ventures: Consultant Visus: Consultant/Equity Owner 2EyesVision: Consultant/Equity Owner



GASCRS Business of Refractive Cataract Surgery — SUMMIT —



Error Source	Contribution*
Post-op IOL Position	35%
Post-Op Corneal Power	15%
Axial Length	17%

* Norrby, S. Sources of error in intraocular lens power calculation. JCRS 2008: 368-76



Lessons from LASIK: UCVA Drives Satisfaction

Ē



• Schallhorn,




Don't Let It Get To This




Managing the Dissatisfied Refractive Surgery Patient

"50 – 80% of the information provided by the clinician is instantly forgotten. Of the balance of information that is remembered, only 50% is remembered correctly."



"50 – 80% of the information provided by the clinician is instantly forgotten. Of the balance of information that is remembered, only 50% is remembered correctly."





Prepare Preoperatively

GASCRS BUSINESS of REFRACTIVE CATARACT SURGERY SUMMIT —

Their EyesTheir Mind


Mrx Tear Film+ Epithelium + Ant Stroma +Lens+ + Vitreous = Vision





Best Corrected Image Quality

- Phoropter
- Gas Permeable Contact Lens




Best Corrected Image Quality


- Phoropter
- Gas Permeable Contact Lens

Irregularity
Easy vs Difficult

Want to find this out preop











Image Quality Optimizing Checklist

Prepare Preoperatively



Their EyesTheir Mind



"One
Year
Journey"

January	February	March
s Preoperative	Intraoperative	Postoperative F s
Tear Film	Visual Axis ID	Tear Film
Epithelium	Refractive Capsulotomy	Refractive Error
Anterior Stroma	IOL Centration	PCO-Refractive YAG
	Posterior Capsule Pristine-ing	Vitreous
April S M T W T F S I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I	S M T W T F S I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I	June S M T W T F S M T W T F S M T W T F S M T W T F S M T W T F S M T U M T F S M T U M T F S M T U M T I I M T I I I I I M T I I I I I M T I I I I I I M I I I I I I I I I M M M M M M M I I I I M M M M M M <thm< th=""></thm<>
July	August	September
	alAdap	
Neur	alAdap	otation
Neur	al Adap November	otation December
Neur	al Adap November	otation December
Neur	al Adap November	otation December

"The first 6 months are spent optimizing your image quality"

"The second 6 months is your brain getting used to your new optical system"

Prepare Preoperatively

.



- •Their Eyes
- •Their Mind
- You and Your Team

Be Confident in the Technology





Modern day implants have an amazing patient satisfaction rate.


Understand Dysphotopsias

GASCRS BUSINESS of REFRACTIVE CATARACT SURGERY SUMMIT —





























Multifocal IOLs PCO, refractive error, OSD

Refractive Tear Film+ Epithelium + Ant Stroma + IOL + Posterior Capsule + Vitreous = Vision Status






Image Quality Optimizing Checklist




Epithelium

Ę









YAG Laser Capsulotomy


Ē




Very common with advanced implants









Respect Low Residcual Refractive Error







Ē




•Small corrections matter...show them...they can decide

2019 ASCRS Clinical Survey – presbyopia correction




WHAT IS THE HIGHEST AMOUNT OF RESIDUAL CYLINDER YOU WOULD FEEL COMFORTABLE PLANNING TO LEAVE IN PATIENTS UNDERGOING IMPLANTATION OF A PRESBYOPIA-CORRECTING IOL? ENTER YOUR RESPONSE IN DIOPTERS.



2019 ASCRS Clinical Survey – presbyopia correction



WHAT IS THE HIGHEST AMOUNT OF RESIDUAL CYLINDER YOU WOULD FEEL COMFORTABLE PLANNING TO LEAVE IN PATIENTS UNDERGOING IMPLANTATION OF A PRESBYOPIA-CORRECTING IOL? ENTER YOUR RESPONSE IN DIOPTERS.



Have a Plan

. . .

©ASCRS Business of Refractive Cataract Surgery — SUMMIT —

Timing of Enhancements

GASCRS Business of Refractive Cataract Surgery — SUMMIT —

• Optic Adjustable

- No previous corneal surgery
- Previous laser corneal surgery
- Previous RK
- Cornea Adjustable
 - 3 months

4 weeks 6 weeks 8 weeks

Enhancement Techniques



- Limbal Relaxing Incisions (LRI)/Astigmatic Keratotomy (AK)
- LASIK/PRK
- Rotate/Reposition Toric IOL

Enhancement Techniques



- Limbal Relaxing Incisions (LRI)/Astigmatic Keratotomy (AK)
- LASIK/PRK
- Rotate/Reposition Toric IOL



AK or LRI


SE = S + (1/2) Cyl +0.5 -1.00 X 150

SE=Plano

AK at 60 degrees









AK














































AK


GASCRS Business of Refractive Cataract Surgery — SUMMIT —














Outcomes of LASIK versus PRK Enhancement in eye with prior cataract surgery

Rohlf, Derek; La Nasa, Anthony; Terveen, Daniel; Shafer, Brian; Thompson, Vance; Berdahl, John

(C)

Journal of Cataract & Refractive Surgery. : August 16, 2022

LASIK provides better and more predictable outcomes in UDVA than PRK in post-cataract enhancement patients, ever




☆ Favorite <u>▶ PDF</u>


Permissions

PAP

Published Ahead-of-Print

This article has not yet been published in final form.






Outcomes of LASIK versus PRK Enhancement in eye with prior cataract surgery

Rohlf, Derek; La Nasa, Anthony; Terveen, Daniel; Shafer, Brian; Thompson, Vance; Berdahl, John

Journal of Cataract & Refractive Surgery. : August 16, 2022

LASIK provides better and more predictable outcomes in UDVA than PRK in post-cataract enhancement patients, even



When to consider a Refractive Enhancement

Vance